Sight Sciences, Inc. (SGHT) stock
Close on Nov 17, 2026Market cap $577.87MP/E –Yield –
Sight Sciences, Inc. grew revenue 9.3% to $83.38M over the twelve months to Jun 30, 2026. Free cash flow was -$23.33M. At the latest close the market valued the company at $577.87M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $577.87M
- P/E ratio
- –
- Price to sales
- 6.93
- Price to book
- 10.93
- Dividend yield
- –
- Free cash flow yield
- -4.04%
Fundamentals
- Revenue
- $83.38M
- Net income
- -$29.76M
- EPS, diluted
- -$0.56
- Free cash flow
- -$23.33M
- Book value per share
- $0.97
- Diluted shares
- 55M
Trading
- Next earnings
- Mar 3, 2027 (estimated, after the close)
- Previous close
- $10.59
- Open
- $10.50
- Day's range
- $10.32 – $10.69
- Volume
- 271,335
- Average volume (20 days)
- 405,763
- Index membership
- Russell 2000 (since Sep 2021)
- 52-week range
- $3.38 – $11.60
- RSI (14 days)
- 64.2
- Volatility (1 year)
- 72.1%
- Relative volume
- 0.64×
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | SGHT | S&P 500 | Difference | SGHT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +26.7% | -4.0% | +30.7 pts | ||
| 3 months | +27.3% | -5.0% | +32.3 pts | ||
| Year to date | +32.3% | +8.2% | +24.0 pts | ||
| 1 year | +49.2% | +11.2% | +38.0 pts | ||
| 3 years | +366.2% | +68.5% | +297.7 pts | +67.1% | +19.0% |
| 5 years | -52.1% | +67.3% | −119.4 pts | -13.7% | +10.8% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sight Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Sight Sciences
Surgical & Medical Instruments & Apparatus
Sight Sciences, Inc. is an ophthalmic medical device company that develops surgical and therapeutic technologies for eye conditions, primarily glaucoma and dry eye disease. The company operates in two segments: Interventional Glaucoma and Interventional Dry Eye. In the Interventional Glaucoma segment, it offers the OMNI Surgical System to reduce intraocular pressure in adults with primary open-angle glaucoma, and the SION Surgical Instrument to excise trabecular meshwork tissue. In the Interventional Dry Eye segment, it offers the TearCare system, which applies localized heat to clear meibomian gland obstructions. Its customers are eyecare professionals, including ophthalmic surgeons, ophthalmologists, and optometrists.
Company profile, executives and historySight Sciences stock: common questions
What is Sight Sciences's stock price?
SGHT closed at $10.49 on Nov 17, 2026, down 0.94% on the day. Over the past 52 weeks it traded between $3.38 and $11.60.
What is Sight Sciences's market cap?
Sight Sciences was worth $577.87M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is SGHT's P/E ratio?
Sight Sciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.56), so it has no meaningful P/E ratio.
How much revenue does Sight Sciences make?
Sight Sciences reported revenue of $83.38M for the twelve months to Jun 30, 2026, up 9.3% from a year earlier.
Does Sight Sciences pay a dividend?
No. Sight Sciences has not paid a cash dividend over the last twelve months.
When does Sight Sciences report earnings next?
Sight Sciences is expected to report Q4 FY2026 results on Mar 3, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has SGHT stock performed over the past year?
Including dividends, SGHT returned +49.2% over the past year, against +11.2% for the S&P 500.
How many SGHT shares are sold short?
1M shares were sold short at the latest FINRA report, 3.08% of the float, or 4.3 days of average trading volume.
Who are Sight Sciences's competitors?
Companies most similar to Sight Sciences by business, industry and size include IRIX, LNSR, LUNG, GKOS, TELA.
See a number that looks wrong?